Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HAPP NASDAQ:SLNO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHAPPHappiness Development Group$1.23+4.2%$1.27$2.08▼$7.40$8.56M0.2314,340 shs55,326 shsSLNOSoleno Therapeutics$52.92+0.0%$42.46$29.43▼$90.32$2.73B-2.232.92 million shs1.17 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHAPPHappiness Development Group0.00%-19.18%-35.87%-25.32%-8.53%SLNOSoleno Therapeutics0.00%+0.23%+33.88%+20.21%-29.72%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHAPPHappiness Development Group$1.23+4.2%$1.27$2.08▼$7.40$8.56M0.2314,340 shs55,326 shsSLNOSoleno Therapeutics$52.92+0.0%$42.46$29.43▼$90.32$2.73B-2.232.92 million shs1.17 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHAPPHappiness Development Group0.00%-19.18%-35.87%-25.32%-8.53%SLNOSoleno Therapeutics0.00%+0.23%+33.88%+20.21%-29.72%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHAPPHappiness Development Group 0.00N/AN/AN/ASLNOSoleno Therapeutics 2.15Hold$76.6744.89% UpsideCurrent Analyst Ratings BreakdownLatest HAPP and SLNO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/17/2026SLNOSoleno Therapeutics Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOverweight ➝ Equal Weight$110.00 ➝ $53.004/17/2026SLNOSoleno Therapeutics Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight$110.00 ➝ $53.004/8/2026SLNOSoleno Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$100.00 ➝ $53.004/7/2026SLNOSoleno Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/7/2026SLNOSoleno Therapeutics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$85.00 ➝ $53.004/7/2026SLNOSoleno Therapeutics Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Hold4/6/2026SLNOSoleno Therapeutics Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/6/2026SLNOSoleno Therapeutics Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/6/2026SLNOSoleno Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Hold$123.00 ➝ $53.003/18/2026SLNOSoleno Therapeutics OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$110.00 ➝ $80.00(Data available from 5/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHAPPHappiness Development Group$95.59M0.09N/AN/A$19.57 per share0.06SLNOSoleno Therapeutics$190.41M14.35$0.43 per share123.78$8.38 per share6.31Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHAPPHappiness Development Group-$49.19MN/A1.35N/AN/AN/AN/AN/AN/ASLNOSoleno Therapeutics$20.89M$0.23230.089.87N/AN/A5.90%4.61%5/6/2026 (Estimated)Latest HAPP and SLNO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2026Q1 2026SLNOSoleno Therapeutics$0.73N/AN/AN/A$93.78 millionN/A2/25/2026Q4 2025SLNOSoleno Therapeutics$0.64$0.80+$0.16$0.80$88.55 million$91.73 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthHAPPHappiness Development GroupN/AN/AN/AN/AN/ASLNOSoleno TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHAPPHappiness Development GroupN/A2.011.94SLNOSoleno Therapeutics0.115.805.55Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHAPPHappiness Development Group15.22%SLNOSoleno Therapeutics97.42%Insider OwnershipCompanyInsider OwnershipHAPPHappiness Development Group15.58%SLNOSoleno Therapeutics6.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHAPPHappiness Development Group2156.96 million5.87 millionNot OptionableSLNOSoleno Therapeutics3051.62 million48.32 millionOptionableHAPP and SLNO HeadlinesRecent News About These CompaniesSLNO DEADLINE ALERT: Hagens Berman Alerts Soleno Therapeutics (SLNO) Investors to Today's Lead Plaintiff Deadline in Securities Class Action2 hours ago | prnewswire.comDEADLINE ALERT for EOSE, SLNO, and NKTR: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders3 hours ago | globenewswire.comSLNO Shareholder Alert: Soleno Therapeutics, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact The Gross Law FirmMay 5 at 9:00 AM | prnewswire.comPortnoy Law Firm Announces Class Action on Behalf of Soleno Therapeutics, Inc. InvestorsMay 5 at 9:00 AM | globenewswire.comSoleno Therapeutics (SLNO) Expected to Announce Quarterly Earnings on WednesdayMay 5 at 5:18 AM | americanbankingnews.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) Given Average Recommendation of "Hold" by BrokeragesMay 5 at 2:42 AM | americanbankingnews.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) Receives Consensus Rating of "Hold" from AnalystsMay 5 at 2:07 AM | marketbeat.comSOLENO THERAPEUTICS DEADLINE TOMORROW: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SLNOMay 4 at 10:46 PM | newsfilecorp.comNSOLENO THERAPEUTICS CLASS ACTION DEADLINE TOMORROW: Bragar Eagel & Squire, P.C. Urges Soleno Therapeutics, Inc. Investors with Significant Losses to Contact the Firm Before May 5th Lead Plaintiff DeadlineMay 4 at 5:47 PM | globenewswire.comDeadline Soon: Soleno Therapeutics, Inc. (SLNO) Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz About Securities Fraud LawsuitMay 4 at 3:35 PM | tmcnet.comSOLENO THERAPEUTICS DEADLINE TOMORROW: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SLNOMay 4 at 12:21 PM | globenewswire.comSLNO INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026May 4 at 12:20 PM | newsfilecorp.comNBronstein, Gewirtz & Grossman LLC Urges Soleno Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor HarmMay 4 at 12:00 PM | globenewswire.comSLNO Deadline: SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud LawsuitMay 4 at 11:45 AM | prnewswire.comSLNO SHAREHOLDER NOTICE: Hagens Berman Alerts Soleno (SLNO) Investors to Pending Securities Fraud Class Action and Upcoming May 5th Lead Plaintiff DeadlineMay 4 at 8:45 AM | globenewswire.comSoleno Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SLNOMay 4 at 4:03 AM | prnewswire.comSLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law FirmMay 4 at 3:06 AM | prnewswire.comSOLENO THERAPEUTICS DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SLNOMay 3 at 10:41 PM | newsfilecorp.comNSOLENO THERAPEUTICS DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SLNOMay 2 at 9:39 PM | newsfilecorp.comNSLNO CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026May 2 at 8:20 AM | newsfilecorp.comNSOLENO THERAPEUTICS DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SLNOMay 1, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHAPP and SLNO Company DescriptionsHappiness Development Group NASDAQ:HAPP$1.23 +0.05 (+4.24%) As of 05/4/2026Happiness Development Group Limited engages in the research, development, manufacture, and sale of nutraceutical and dietary supplement products in the People's Republic of China and internationally. The company's product category includes lucidum spore powders, cordyceps mycelia, Ejiao products, American ginseng products, other traditional Chinese herbal and animal extracts, vitamins, minerals, and amino acids. It also offers product marketing and e-commerce agency operation services under the Happy Buy platform to small and middle size businesses; and e-commerce solutions, internet information, and advertising services to the online stores or manufactures. In addition, the company provides secure transaction environment, automobile procurement, and financial services for automobile manufacturers under the Taochejun automobile sales platform. It sells its products through distributors, large-scale chain drugstores, malls, and supermarkets under the Happiness brand. The company was formerly known as Happiness Biotech Group Limited and changed its name to Happiness Development Group Limited in October 2022. Happiness Development Group Limited was founded in 2004 and is headquartered in Nanping, the People's Republic of China.Soleno Therapeutics NASDAQ:SLNO$52.92 +0.02 (+0.03%) As of 03:25 PM Eastern This is a fair market value price provided by Massive. Learn more.Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas onsemi Stock Dips After Earnings: Why the Dip Is Buyable Nebius Breaks Out to All-Time Highs—Here's What's Driving It. 3 Reasons Analysts Love DexCom Atomic Dividends: Big Tech's New Energy Bet Monolithic Power Systems: AI Stock Beat, Raised and Upgraded Post-Earnings Leading Insider Sales: April Activity Ramps in These Stocks The New Fed Chair Trade: Who Wins When Warsh Takes the Helm? A Prada Payday: Is AMC Back in Style? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
